Life Sciences Insights is our digital magazine that explores the latest thought leadership from California’s life sciences sector. We release a new edition each quarter, exploring a specific topic or theme. Life Sciences Insights features the perspectives, ideas, and experiences of our 1,200+ member organizations who are working to deliver innovative solutions for healthier lives, through science.

Have a topic you’d like to suggest we explore in our next edition? Contact [email protected] to submit your proposal!

Call For Content Submissions

Many of CLS’s members are committed to delivering progress to address the more than 7,000 known rare diseases that impact up to 30 million Americans. Development of treatments for these diseases is one of the most exciting fields of innovation in the life sciences sector. ThenInflation Reduction Act implemented policies that will subject rare disease medicines to government price setting if a company pursues more than one indication for an orphan drug. These types of policies will, ultimately, impact the patients that many of our organizations aim to treat. Considering these types of policies impacting patients, if your organization is working on developing products to treat rare diseases, we want to hear from you!

  1. What is your organization doing, because of policies like the IRA, around rare disease and drug development? Are you considering policies like these when considering the future of your development pipelines? Are you seeing any decline in investments in rare disease?
  2. What does the future hold for advancements in this space?  What excites you the most?
  3. What can California do, specifically, to improve patient access to innovative rare disease treatments, including historically underserved communities?
GUIDELINES

  1. The response should be of educational benefit (e.g., business use case, best practice, analysis, or opinion), and should not be promotional.
  2. Article length should be between 200 to 400 words.
  3. Submitting company must be a member of California Life Sciences.

Selected responses will be featured in a special edition of our newsletter, CLS Bulletin: Life Sciences Insights, in the CLS Community Portal, and amplified via CLS social media channels as part of a campaign tied to CLS’s Spring Fly-In where CLS board members will gather in Washington, D.C. to educate California’s congressional delegation on key policy issues, including but not limited to the ORPHAN Cures Act.

Please click here to submit your article no later than Friday, April 19th. Should you have any questions, please contact Morgan Pegus-Thomas.

 

 Life Science Insights Archive